Clinical Trials
17 trialsNCT00588770 2026-05-29
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT03360890 2026-03-13
iPRIME
University of Chicago
Phase 2 Active not recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT00040807 2023-06-18
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05008237 2021-08-17
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
Samsung Medical Center
Phase 2 Unknown
NCT02035527 2018-05-24
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00006107 2017-06-16
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00937417 2017-04-24
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00003565 2016-07-14
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT00055770 2013-11-25
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00014456 2013-08-28
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00084435 2012-06-14
S0217
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01313390 2011-12-12
DORA
University College, London
Phase 1/2 Terminated
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed